

RWTH Technology Highly Efficient and Selective Inhibitors Targeting BET Bromodomains

RWTH Innovation GmbH

RWTH Technology
#2252

Fields of application

Pharmaceutical Development;
Oncology

Keywords

#BET inhibitor, #Sulfoximines, #Sulfondiimides, #Sulfonimidamides

Contact


RWTH Innovation
Campus-Boulevard 57
52074 Aachen
GERMANY

Tel.: +49 241 80-96610
Fax: +49 241 80-692614

info@rwth-innovation.de
www.rwth-innovation.de


A

Treatment with DMSO or 5 μ M PFI-1 or MF2-S for 72 h



B

Treatment with DMSO or 5 μ M PFI-1 or MF2-S for 72 h



Investigation of the efficacy of the novel compounds on cell viability (A) and proliferation (B) of HEL, Molm14 and K562 cells. (A) Viability was evaluated after 72 hours by trypan blue staining and cell number was calculated using a Casy cell counter. Comparison of the three different cell lines are illustrated at compound concentrations of 5 μ M. Data are shown as mean \pm SD. Statistics: PFI-1 was compared to MF2-S. * $p < 0.05$, *** $p < 0.001$. ns - not significant

Challenge

BET proteins are important because they regulate both normal transcription processes as well as the transcription of oncogenes such as c-myc and Bcl-2 in various types of cancer. An efficient and selective inhibition of the BET proteins is therefore of great importance for cancer therapies. Various compounds, including benzenesulfonamide derivatives are known to possess this property. However, there is a great desire for further, more selective inhibitors.

Solution

The use of sulfoximine, sulfondiimide and sulfonimidamide derivatives allows to generate novel molecules with a stereogenic sulfur atom. The utilization of this chirality provides new, highly effective and selective BET inhibitors.

Advantages

- Novel BET inhibitors bearing a stereocenter
- Chirality is the key to high efficacy and selectivity

Status

- International patent application pending and German patent application pending.
- Proof of concept and Ongoing research

RWTH Aachen University is looking for partners for patent exploitation.

Further details

- Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies
B. Altenburg, M. Frings, J.-H. Schöbel, J. Goßen, K. Pannen, K. Vanderliek, G. Rossetti, S. Koschmieder, N. Chatain, C. Bolm, *ACS Med. Chem. Lett.* **2020**, <https://doi.org/10.1021/acsmchemlett.9b00625>.